Anti-IGF1R Antibody scFv (MOM-18209-S(P))
|Recombinant Anti-Human IGF1R Antibody scFv Fragment
- Product Overview
- Recombinant Human Antibody scFv Fragment is directed against Human IGF1 Receptor, expressed in E. coli
- scFv Fragment from Human IgG1 - kappa
- Suitable for use in ELISA, WB, Neut and most other immunological methods.
- Specific Activity
- Tested positive against native antigen.
- >95.0%. Determined by analysis by RP-HPLC & analysis by SDS-PAGE.
- Store it under sterile conditions at -20°C upon receiving. Recommend to pack the protein into smaller quantities for optimal storage.
- Antigen Description
- Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins.
- ATP binding; identical protein binding; insulin binding; insulin receptor binding; insulin receptor substrate binding; insulin-like growth factor I binding; insulin-like growth factor binding; insulin-like growth factor-activated receptor activity; nucleotide binding; phosphatidylinositol 3-kinase binding; protein binding; protein tyrosine kinase activity; receptor activity;
- IGF1R; insulin-like growth factor 1 receptor; CD221; IGFIR; IGFR; JTK13; MGC18216; IGF-I receptor; soluble IGF1R variant 1; soluble IGF1R variant 2; insulin-like growth factor I receptor; MGC142170; MGC142172;
All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic or any in vivo human use.